0DZ0.LSE ChemoMetec A/S
- Market cap
- DKK 12.1B
- P/E
- 108.6x
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is 0DZ0.LSE undervalued?
Graham numberThe Graham number of ChemoMetec A/S cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ChemoMetec A/S fundamental analysis
No fundamental analysis for ChemoMetec A/S yet.
ChemoMetec A/S stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ChemoMetec A/S
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer;…
Full company profileFinancial statements of ChemoMetec A/S are not available yet.
ChemoMetec A/S dividends
ChemoMetec A/S has not paid dividends in the last 4 fiscal years.
Who owns ChemoMetec A/S
- Insiders 3.73%
- Institutions 52.82%
- Public & others 43.45%
- Shares outstanding 15.4M
- Free float 16.5M
ChemoMetec A/S company profile
- Company name
- ChemoMetec A/S
- Ticker
- 0DZ0.LSE
- ISIN
- DK0060055861
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Medical Devices
- Employees
- 174
- Fiscal year end
- June
- Address
- Gydevang 43, Allerød, Denmark, 3450
- Phone
- 45 48 13 10 20
- Website
- chemometec.com
About ChemoMetec A/S
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter NC-203, a high-precision cell counter designed to deliver complex cell samples; NucleoCounter SP-100, an automated sperm cell counter for use in animal reproduction; and XcytoMatic 40, a cell density and viability analyzer. In addition, the company provides consumables comprising cassettes, reagents, lysis, and slides; accessories, which include cables, power supplies, software, and labware products, as well as service and validation plans and training. Further, it develops XcytoMatic 30 cell counter and Xcyto 5. ChemoMetec A/S was incorporated in 1997 and is headquartered in Allerød, Denmark.
ChemoMetec A/S management
6- Mr. Martin Helbo BehrensChief Executive Officer · born 1992
- Mr. Phillip Massie PriceChief Financial Officer · born 1992
- Mr. Bo Melholt NielsenChief Technology & Automation Officer
- Mr. Christopher Runchel M.Sc., Ph.D.Chief Sales Officer
- Mr. Søren KjærulffHead of R&D
- Emil SondergaardChief Commercial Officer